Survival after hematopoietic cell transplant (HCT) has improved since 2000. 1 However, it is unclear whether improvement in survival after grade 3-4 acute GVHD (aGVHD) has paralleled the improvement in survival after HCT. This would be expected, as new immunosuppressive drugs and antimicrobial treatment, and prophylaxis options have become available since 2000. We set out to determine the long-term survival of patients with grade 3-4 aGVHD at our institution after 2000, as well as to review the literature to identify survival of this patient population before and after 2000.
For Methods, see Supplementary Material online. Briefly, recipients of marrow or blood stem cells were studied. Conditioning (always myeloablative) and GVHD prophylaxis typically consisted of fludarabine þ BU þ antithymocyte globulin
Fifty of 718 patients (7%) developed grade 3 or 4 aGVHD at our institution between January 1999 and March 2010 (Supplementary Table 1 ). Twelve (24%) were steroid-responsive and 38/50 (76%) were steroid-refractory ( Figure 1 ). Of the 38 steroid-refractory patients, 34 were treated with ATG (alone or in addition to other therapy-Supplementary Table 2), 2 were treated with daclizumab and 2 died too early to proceed to a second line therapy. Median time from the onset of aGVHD to the beginning of ATG therapy was 15 days (range, 4-63). Forty-one percent (14/34) of patients responded to ATG (achieved CR or PR) at 4 weeks and this declined to 21% (7/34) at 12 weeks. Skin aGVHD demonstrated the best response (80% at 4 weeks) (Supplementary Table 3 ). Five ATG-treated patients were tapered off of all immunosuppression at a median of 975 days after beginning ATG (range 258-1116). Four of these patients are currently alive. Three of the five patients had prolonged immunosuppression for chronic GVHD. The remaining 29 patients died while on immunosuppression at a median of 37 days after starting ATG (range 2-959). The 34 ATG-treated patients developed 75 microbiologically proven infections, including 40 bacterial, 27 viral and 8 fungal infections. The 12 steroidresponsive patients were treated with systemic corticosteroids for a median of 130 days (range 55-277 days). Three of these patients died while still receiving corticosteroids.
Survival of the entire cohort of 50 patients was 30% (15/50) at 1 year, 20% (10/50) at 2 years and 8% (4/48, excluding 2 patients who have not yet reached 5 years of follow-up) at 5 years. 2 There was no significant difference in survival between steroidresponsive and refractory groups: 17% (2/12) of steroidresponsive patients are alive at 6.9 and 7.0 years post transplant, and 11% (4/38) steroid-refractory patients are alive at 3.6, 4.3, 11.4 and 12.8 years post transplant (P ¼ 0.62, Fisher's exact test) (Supplementary Figure 1) . As expected, GVHD and infection were the predominant causes of death (Supplementary Table 4) .
For the literature review, 19 of 40 reviewed studies met our criteria (see Supplementary Material) and were thus included (Table 1) . Most excluded studies (16 of 21) had o1 year follow-up of surviving patients. For transplants performed before 2000, 10 studies were included. Survival ranged from 4 to 33% (median, 11%) at 1-4 years. For transplants performed after 2000, nine studies were included. Two of them began enrollment in 1999, but were included here as most enrollment occurred after 2000. Survival ranged from 0% (reported in 3 studies) to 43% (median, 17%) at 1-3 years.
Thus, the long-term survival of patients with grade 3-4 aGVHD appears to have improved little, if at all. In our relatively large cohort of grade 3-4 aGVHD patients studied post 2000 2-year survival was 20% and 5 year survival 8%. This is consistent with the median survival in the post 2000 published studies of 17% at 1-3 years. While many studies of therapy for steroid-refractory aGVHD report reasonable or even excellent (80-100%) response rates (Table 1) , this clearly does not translate into similar numbers of patients surviving long-term. Similarly, MacMillanet al.
3 found no correlation between response to ATG at day 28 and survival in patients with aGVHD. This calls into question the utility of trials with short follow-up and the notion that response at 28 days is predictive of long-term outcome, as recently suggested. 4 More studies with long-term follow-up are needed; a registry study could address this need. We are aware of only two studies other than ours reporting at least one patient surviving 45 years after grade 3-4 aGVHD (see Table 1 ).
Admittedly, many of the studies reviewed are small, early-phase trials and patients presented may not be entirely representative of the whole grade 3-4 aGVHD population. That being said, these are the only survival data extractable from the literature and survival of unselected grade 3-4 aGVHD patients at our institution does not differ greatly. The routine use of ATG for GVHD prophylaxis at our institution might limit the generalizability of our results, as our patients who developed GVHD may have been less responsive to further anti-T-cell therapy. However, the survival of our patients is (Table 1) , the vast majority of which did not use ATG in GVHD prophylactic regimens. An additional and unexpected finding in our study was the nonsignificant difference in long-term survival between our steroidrefractory and steroid-responsive cohorts. This could have occurred because treatment with rabbit ATG had a small effect (as opposed to horse ATG that appears to have no anti-GVHD activity, at least for prophylaxis 5, 6 ), bringing the survival of steroidrefractory patients close to that of steroid-responsive patients, or because the sample size was too small to detect a significant difference.
In conclusion, despite the availability of new immunosuppressive and antimicrobial drugs, the prognosis of grade 3-4 aGVHD continues to be dismal. The reason for this remains unclear. Perhaps, cells that are not targeted by immunosuppressive therapies (for example, endothelial cells) are involved in the pathogenesis of severe aGVHD. 7 There is a great need for research on aGVHD pathogenesis and therapy. Until then, the only way of reducing the incidence of severe aGVHD may lie in aGVHD prophylaxis 8 and/or pre-emptive therapy, 9 while balancing the graft-versus-tumor effect.
CONFLICT OF INTEREST
JS received a grant from Genzyme/Sanofi. All other authors declare no conflict of interest. 
